drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (biologic)
drug_description
A first-in-human Claudin 18.2–targeted antibody-drug conjugate; a monoclonal antibody binds CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload causing Topo‑I inhibition, DNA damage, and tumor cell death; administered every 3 weeks.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Monoclonal antibody targets CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload via linker cleavage, leading to Topo-I inhibition, DNA damage, and tumor cell death.
drug_name
XNW27011
nct_id_drug_ref
NCT06792435